Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.

Liver international : official journal of the International Association for the Study of the Liver - 1 Mar 2025

Petta Salvatore, Armandi Angelo, Bugianesi Elisabetta

Abstract excerpt

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogenous clinical and histopathological entity, where multiple metabolic co-factors are intertwined with high interindividual variability. The impact and severity of each factor (including obesity and type 2 diabetes) define a systemic dysmetabolism that can lead to either advanced liver disease and its complication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyltransferases
Share to Disease Progression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Lipase

Share to Membrane Proteins

Share to Non-alcoholic Fatty Liver Disease

Share to Phospholipases A2, Calcium-Independent

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 39412170
DOI: 10.1111/liv.16133
PMCID: PMC11815615

Genes

PNPLA3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.PMID 39412170Read ↗

PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Semantic proximity Read ↗

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease.Semantic proximity Read ↗

Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysisSemantic proximity Read ↗

PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: A meta-analysis of observational studies.Semantic proximity Read ↗

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Semantic proximity Read ↗

Function of PNPLA3 I148M-Lessons From In Vivo Studies in Humans.Semantic proximity Read ↗

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.Semantic proximity Read ↗

Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatmentSemantic proximity Read ↗

Integrating PNPLA3 into clinical risk prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.